[HTML][HTML] Effect of multidrug-resistant 1 (MDR1) and CYP3A4* 1B polymorphisms on cyclosporine-based immunosuppressive therapy in renal transplant patients
MJ Kotowski, A Bogacz… - Annals of …, 2019 - ncbi.nlm.nih.gov
Background Immunosuppressive drugs such as cyclosporine A (CsA) are characterized by a
narrow therapeutic range and high interindividual pharmacokinetic variations. Therefore, the …
narrow therapeutic range and high interindividual pharmacokinetic variations. Therefore, the …
Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation
FL Ng, DW Holt, IAM MacPhee - Expert Opinion on …, 2007 - Taylor & Francis
Existing immunosuppressive therapies used for solid-organ transplantation have narrow
therapeutic indices, whereby underdosing is associated with acute immunological rejection …
therapeutic indices, whereby underdosing is associated with acute immunological rejection …
Update on the clinical pharmacogenomics of organ transplantation
GJ Burckart, S Amur - Pharmacogenomics, 2010 - Taylor & Francis
Organ transplantation suffers from a static graft and patient survival rate, and a high
incidence of serious adverse drug effects. The pharmacogenomics of organ transplantation …
incidence of serious adverse drug effects. The pharmacogenomics of organ transplantation …
Toward personalized medicine in renal transplantation
I Lampreabe, FJG de los Rios, AA Gutiérrez… - Transplantation …, 2010 - Elsevier
BACKGROUND: The pharmacokinetics of tacrolimus (TRL) are clearly affected by genetic
polymorphisms in drug-metabolizing enzymes, which lead to large interindividual …
polymorphisms in drug-metabolizing enzymes, which lead to large interindividual …
The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?
DA Hesselink, T Van Gelder… - Pharmacogenomics, 2005 - Taylor & Francis
The immunosuppressive drugs cyclosporin (CsA) and tacrolimus (Tac) are widely used to
prevent acute rejection following solid-organ transplantation. However, the clinical use of …
prevent acute rejection following solid-organ transplantation. However, the clinical use of …
Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes
B Tavira, EC Garciá, C Díaz-Corte, F Ortega… - Clinical chemistry and …, 2011 - degruyter.com
Abstract Background: Tacrolimus (Tac) is an immunosuppressive drug used to prevent post-
transplant (PT) organ rejection. Continuous Tac monitoring is necessary to adjust the dose …
transplant (PT) organ rejection. Continuous Tac monitoring is necessary to adjust the dose …
Individualization of immunosuppression: concepts and rationale
MD Wavamunno, JR Chapman - Current Opinion in Organ …, 2008 - journals.lww.com
Therapeutic drug monitoring remains the most widely used method for individualizing
immunotherapy. Improvements in molecular technology have enabled identification of …
immunotherapy. Improvements in molecular technology have enabled identification of …
The role of genetics in drug dosing
N Ware - Pediatric Nephrology, 2012 - Springer
Renal transplantation is the optimal form of renal replacement therapy (RRT) for the majority
of patients. Both short-and long-term graft rejection are well recognized complications …
of patients. Both short-and long-term graft rejection are well recognized complications …
Population pharmacokinetic approach of immunosuppressive therapy in kidney transplant patients
B Golubovic, M Prostran, B Miljkovic… - Current Medicinal …, 2016 - ingentaconnect.com
Immunosuppressive therapy is the cornerstone of successful kidney transplantation.
Frequently used immunosuppressives are cyclosporine, tacrolimus, sirolimus and …
Frequently used immunosuppressives are cyclosporine, tacrolimus, sirolimus and …
ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients
M García, RM Macías, JJ Cubero, J Benítez… - European journal of …, 2013 - Springer
Purpose There is a great deal of controversy regarding the clinical impact of genetic variants
in patients receiving cyclosporine (CsA) as immunosuppressant therapy. We have …
in patients receiving cyclosporine (CsA) as immunosuppressant therapy. We have …